A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Condition:   Metastatic Pancreatic Cancer Interventions:   Drug: Donafenib;   Drug: S1 Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials